Buy Retatrutide – Premium Triple GIP/GLP-1/Glucagon Receptor Agonist for Research

Welcome to Liaocheng Yixin Company, your trusted source to buy retatrutide peptide for research. As a licensed peptide synthesis manufacturer operating from our facility in Shandong Province, China, we provide high-quality research compounds for the global scientific community.

Retatrutide is a synthetic 39-amino-acid peptide that functions as a triple agonist targeting the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors . Engineered from a GIP peptide backbone and conjugated to a C20 fatty di-acid moiety to enable albumin binding and extend its half-life, retatrutide represents a novel class of investigational compounds designed to maximize metabolic improvement through complementary hormonal pathways . When you buy retatrutide for research, you gain access to a well-characterized tool for advanced metabolic, obesity, and receptor pharmacology studies. 

What is Retatrutide?retatrutide peptide for research

Retatrutide (LY3437943) is the first triple agonist to combine GIP, GLP-1, and glucagon receptor agonism in a single molecule . Its mechanism adds a distinct glucagon component to the established GIP/GLP-1 pathway, which current leading agents like tirzepatide do not target. This glucagon arm appears to increase energy expenditure and liver fat burning, setting retatrutide apart from mono- or dual-incretin therapies .

Key Identifiers:

• CAS Number: Not specified

• retatrutide peptide for research

• Molecular Formula: 39-amino-acid peptide

• Molecular Weight: Not specified

• Synonyms: LY3437943

• Purity: ≥99% verified by HPLC

Mechanism of Action in Research

Triple Receptor Engagement

Retatrutide simultaneously engages three distinct receptor families :

• GIP receptor: Enhances glucose-dependent insulin secretion and may contribute to appetite suppression

• retatrutide peptide for research

• GLP-1 receptor: Reduces appetite via hypothalamic receptors, increases insulin secretion, and delays gastric emptying

• Glucagon receptor: Increases energy expenditure, enhances fat oxidation and thermogenesis, and promotes liver fat burning

Dual-Function Mechanism

The glucagon receptor component distinguishes retatrutide from other agents in its class. While GIP and GLP-1 agonism predominantly reduce food intake, the glucagon arm works on the output side of the energy equation, increasing energy expenditure and metabolic rate . Research in preclinical models suggests that retatrutide treatment leads to weight loss through mechanisms beyond chronic appetite suppression, such as enhanced energy expenditure . This dual mechanism—appetite reduction plus energy expenditure—likely drives the larger weight-loss numbers observed in clinical trials .

Potency Profile

Retatrutide has approximately 2.5-times lower potency at the GLP-1 receptor than human GLP-1, 8.9-times higher potency at the GIP receptor than human GIP, and 2.9-times lower potency at the glucagon receptor than human glucagon .

Research Applications

Metabolic and Obesity Studies

Retatrutide has demonstrated substantial efficacy in clinical trials. In the phase 3 TRIUMPH-1 trial involving 2,339 adults with obesity, participants achieved average weight loss of :

• 28.3% (~70 lb) on the 12 mg dose

• 25.9% (~64 lb) on the 9 mg dose

• 19.0% (~47 lb) on the 4 mg dose

These results represent the greatest weight loss ever achieved in a clinical trial for any obesity medication .

Type 2 Diabetes Research

In the phase 3 TRANSCEND-T2D-1 trial, participants with recent-onset type 2 diabetes treated with retatrutide experienced :

• Up to a 2% reduction in HbA1c

• retatrutide peptide for research

• 16.8% reduction in body weight (average loss of 36.6 lbs)

• Improvements in LDL cholesterol, triglycerides, and blood pressure

Metabolic Dysfunction Research

Retatrutide is being studied in phase 3 trials for chronic low back pain, obstructive sleep apnea (OSA), and metabolic dysfunction-associated steatotic liver disease (MASLD) . Preclinical research indicates retatrutide may alleviate adipose tissue fibrosis via metabolic reprogramming and tissue repair .

Cardiovascular Risk Research

Retatrutide has demonstrated improvements in key cardiovascular risk factors, including reductions in LDL cholesterol, triglycerides, and blood pressure. In TRIUMPH-3, 12 mg doses led to a 37% reduction in triglycerides and a 51.2% reduction in high-sensitivity C-reactive protein, a key inflammatory marker .

Important Research Considerations

Regulatory Status

Retatrutide is an investigational compound not currently approved by any regulatory agency . It is legally available only through clinical trials sponsored by its developer. Illicit products claiming to be retatrutide may contain unknown ingredients, harmful contaminants, and impurities . This product is manufactured strictly for research use only.

Submission Timeline

Based on positive phase 3 results, regulatory submission is planned for the first quarter of 2027 .

Safety Profile

The most common side effects reported in clinical trials are gastrointestinal in nature—nausea, vomiting, diarrhea, and constipation—similar to other agents in this class . Effects are dose-dependent and cluster around dose step-ups. Retatrutide discontinuations due to side effects in TRIUMPH-1 were 4.1%, 6.9%, and 11.3% at 4 mg, 9 mg, and 12 mg, respectively .

Rapid weight loss with retatrutide raises considerations for muscle and bone health, and gallstone risk—in line with gallbladder warnings across this drug class . Resting heart rate rises have been observed (approximately 5-11 bpm), which may matter more in patients with increased cardiac risk .

Why Choose Liaocheng Yixin Company?

When you buy retatrutide peptide for research, quality and reliability are paramount. Here’s why researchers trust us:

Manufacturer-Direct Quality

We are a legitimate, licensed peptide synthesis company with a physical headquarters in Shandong Province, China. Our facility maintains strict quality control standards.

Verified Purity Standards

Every batch undergoes rigorous testing using HPLC and mass spectrometry. Our retatrutide meets ≥99% purity standards. Certificates of Analysis are available upon request.

Research-Grade Specifications

• Purity: ≥99% verified by HPLC

• Class: Triple GIP/GLP-1/glucagon receptor agonist

• Sequence: 39-amino-acid peptide

• Appearance: Lyophilized powder

• retatrutide peptide for research

• Storage: Store powder at -20°C in a sealed, desiccated container, protected from light and moisture

• Form: Lyophilized powder for research use

Quality Assurance & Testing

Every batch undergoes comprehensive quality control:

1. Synthesis by experienced chemists using solid-phase peptide synthesis

2. Purification via preparative HPLC

3. Analysis using HPLC for purity verification

4. retatrutide peptide for research

5. Mass Spectrometry for molecular weight confirmation

6. Packaged under sterile conditions for research use

FAQ Section

: What is retatrutide and how does it work in research?

A: Retatrutide is a 39-amino-acid peptide that acts as a triple agonist targeting the GIP, GLP-1, and glucagon receptors . It functions through two complementary mechanisms: appetite reduction (via GIP/GLP-1 pathways) and increased energy expenditure (via glucagon receptor activation) . This dual mechanism distinguishes it from mono- and dual-incretin therapies.Q: What research applications use retatrutide?

A: Retatrutide is used in metabolic and obesity studies, type 2 diabetes research, MASLD research, obstructive sleep apnea studies, chronic low back pain investigations, and receptor pharmacology research.

: Is retatrutide approved for human use?

A: No. Retatrutide is an investigational compound not currently approved by any regulatory agency . Regulatory submission is planned for the first quarter of 2027 . This product is strictly for research use only.

: What purity level can I expect?

A: All batches are tested to ensure ≥99% purity by HPLC analysis. Certificates of Analysis are available upon request.

: Is this product for human use?

A: No. Our retatrutide is manufactured strictly for research use only (RUO). It is not intended for human consumption or clinical applications.

When you need premium retatrutide peptide for research for your metabolic, obesity, or receptor pharmacology studies, choose a manufacturer that prioritizes quality, transparency, and reliability. Liaocheng Yixin Company combines expert peptide synthesis capabilities with rigorous quality control to deliver research materials you can trusretatrutide peptide for researcht.